Globally, the percentage of positive cases of ROS1 rearrangement was a little bit lower than that described in the literature since our cohort of NS-NSCLC patients contains more than 30% of patients with early-stage disease, which is associated with a lower number of rearranged ROS1 tumors [20]. Here, ROS1 is linked to non-small cell lung carcinoma.